Foghorn Therapeutics Inc. expected to post a loss of 76 cents a share - Earnings Preview
07/03/2024 12:03
* Foghorn Therapeutics Inc. FHTX.OQ FHTX.O is expected
to show
a rise in quarterly revenue when it reports results on March 9
(estimated) for the period ending December 31 2023
* The Cambridge Massachusetts-based company is expected to
report
a 10.5% increase in revenue to $4.622 million from $4.18 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for Foghorn Therapeutics
Inc. is
for a loss of 76 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Foghorn
Therapeutics Inc. is $14.50, above its last closing price
of $6.79.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.74 -0.75 -0.34 Beat 54.7
Jun. 30 2023 -0.74 -0.73 -0.70 Beat 4.8
Mar. 31 2023 -0.68 -0.72 -0.73 Missed -0.7
Dec. 31 2022 -0.71 -0.62 -0.69 Missed -11.7
Sep. -0.67 -0.62 -0.62 Met 0
30 2022
Jun. 30 2022 -0.65 -0.59 -0.66 Missed -11.4
Mar. 31 2022 -0.54 -0.52 -0.65 Missed -24.4
Dec. 31 2021 -0.49 -0.49 -0.74 Missed -51.6
This summary was machine generated March 7 at 12:02 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)